Goldman Sachs upgraded GlaxoSmithKline (NYSE: GSK) from Neutral to Buy. Analyst Keyur Parekh thinks there is limited risk to the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE